Cholecystokinin stimulates a specific ribosomal S6 kinase in rat pancreatic acini

Cholecystokinin (CCK) Regulation of Pancreatic Acinar Cells: Physiological Actions and Signal Transduction Mechanisms

Pancreatic acinar cells synthesize and secrete about 20 digestive enzymes and ancillary proteins with the processes that match the supply of these enzymes to their need in digestion being regulated by a number of hormones (CCK, secretin and insulin), neurotransmitters (acetylcholine and VIP) and growth factors (EGF and IGF). Of these regulators, one of the most important and best studied is the gastrointestinal hormone, cholecystokinin (CCK). Furthermore, the acinar cell has become a model for seven transmembrane, heterotrimeric G protein coupled receptors to regulate multiple processes by distinct signal transduction cascades. In this review, we briefly describe the chemistry and physiology of CCK and then consider the major physiological effects of CCK on pancreatic acinar cells. The majority of the review is devoted to the physiologic signaling pathways activated by CCK receptors and heterotrimeric G proteins and the functions they affect. The pathways covered include the traditional second messenger pathways PLC-IP3-Ca²⁺ , DAG-PKC, and AC-cAMP-PKA/EPAC that primarily relate to secretion. Then there are the protein-protein interaction pathways Akt-mTOR-S6K, the three major MAPK pathways (ERK, JNK, and p38 MAPK), and Ca²⁺ -calcineurin-NFAT pathways that primarily regulate non-secretory processes including biosynthesis and growth, and several miscellaneous pathways that include the Rho family small G proteins, PKD, FAK, and Src that may regulate both secretory and nonsecretory processes but are not as well understood. © 2019 American Physiological Society. Compr Physiol 9:535-564, 2019.

Translational control of protein synthesis in pancreatic acinar cells

Translational control of protein synthesis in the pancreas is important in regulating growth and the synthesis of digestive enzymes. Regulation of translation is primarily directed at the steps in initiation and involves reversible phosphorylation of initiation factors (eIFs) and ribosomal proteins. Major sites include the assembly of the eIF4F mRNA cap binding complex, the activity of guanine nucleotide exchange factor eIF2B, and the activity of ribosomal S6 kinase. All of these involve phosphorylation by different regulatory pathways. Stimulation of protein synthesis in acinar cells is primarily mediated by the phosphatidylinositol 3-kinase-mTOR pathway and involves both release of eIF4E (the limiting component of eIF4F) from its binding protein and phosphorylation of ribosomal S6 protein by S6K. eIF4E is itself phosphorylated by a distinct pathway. Inhibition of acinar protein synthesis can be mediated by inhibition of eIF2B following phosphorylation of eIF2alpha.

Regulation of the initiation of pancreatic digestive enzyme protein synthesis by cholecystokinin in rat pancreas in vivo

BACKGROUND & AIMS

Cholecystokinin (CCK) is known to stimulate the synthesis of digestive enzymes in the pancreas at the translational level. We investigated in vivo the biochemical regulation of initiation factors important for the stimulation of translation of digestive enzyme protein in rat pancreas by CCK.

METHODS

Intraperitoneal injection of CCK or intragastric administration of a trypsin inhibitor to elicit endogenous CCK release was followed by removal and preparation of pancreas for protein evaluation. Isoelectric focusing was used to evaluate the phosphorylation of the initiation factor eIF4E, and Western blotting and immunoprecipitation followed by Western blotting were used to study the phosphorylation state and amount of other interacting factors.

RESULTS

CCK treatment induced a time- and dose-dependent phosphorylation of pancreatic eIF4E and its binding protein (PHAS-I). Because the release of eIF4E from its binding protein as a result of phosphorylation is followed by formation of a messenger RNA cap-binding complex that includes the initiation factor eIF4G, we evaluated the association of eIF4G with released eIF4E and showed that it was increased by CCK. These events occurred over a range of CCK doses from 0.2 to 5 microg/kg. We also evaluated the effect of endogenous CCK by administering a synthetic trypsin inhibitor, camostat (100 mg/kg). Camostat treatment markedly increased the phosphorylation of both PHAS-I and eIF4E and the formation of eIF4E-eIF4G complex. Thus, both exogenous and endogenous CCK activate translational initiation factors in vivo.

CONCLUSIONS

Activation of translational machinery necessary for initiation of protein synthesis likely contributes to the normal postprandial synthesis of pancreatic digestive enzymes.

Regulation of protein synthesis by cholecystokinin in rat pancreatic acini involves PHAS-I and the p70 S6 kinase pathway

BACKGROUND & AIMS

Cholecystokinin (CCK) stimulates protein synthesis in pancreatic acini at the translational level, although the signaling mechanisms involved remain uncharacterized. Two intermediates controlling translation are p70 S6 kinase and PHAS-I. We previously showed that CCK activates p70 S6K in pancreatic acini through phosphatidylinositol 3-kinase (PI 3K). In the present study we investigated the role of PI 3K, p70 S6K, and PHAS-I in mediating CCK-stimulated protein synthesis.

METHODS

Protein synthesis was measured by [35S]methionine incorporation into pancreatic protein using acini from rats with streptozotocin-induced diabetes. p70 S6 K activity was measured. PHAS-I was identified by Western analysis. PHAS-I/eIF-4E association was measured as the amount of PHAS-I recovered after purification of translation factor eIF-4E by 7-methyl guanosine triphosphate-Sepharose.

RESULTS

Rapamycin and PI 3K inhibitors, wortmannin and LY294002, blocked CCK-stimulated p70 S6K activity. Rapamycin inhibited basal protein synthesis and blocked the increase to all CCK concentrations. Wortmannin and LY294002 dose-dependently inhibited basal and CCK-stimulated protein synthesis and also blocked insulin-stimulated protein synthesis. CCK dose-dependently increased PHAS-I phosphorylation via a rapamycin- and LY294002-sensitive pathway and decreased the amount of PHAS-I associated with eIF-4E. Rapamycin and LY294002 eliminated this effect of CCK.

CONCLUSIONS

CCK stimulation of protein synthesis in pancreatic acini is sensitive to rapamycin and PI 3K inhibitors and involves PHAS-I phosphorylation and its association with eIF-4E.

p70s6k is activated by CCK in rat pancreatic acini

The expression and activity of p70s6k-p85s6k in isolated rat pancreatic acini were revealed by Western blotting, immunoprecipitation, and kinase assay. Cholecystokinin (CCK) stimulation of p70s6k activity was biphasic, with an early phase maximum at 5 min and a late phase maximum at 60 min. The threshold concentration of CCK to increase p70s6k activity was 3 pM, and the maximal effect was seen at 1 nM CCK. Carbachol and bombesin, but not vasoactive intestinal peptide, also activated p70s6k. The protein kinase C (PKC) activator (12-O-tetradecanoylphorbol 13-acetate), the calcium ionophore (ionomycin), and a derivative of adenosine 3',5'-cyclic monophosphate induced only a slight increase in p70s6k activity. Rapamycin potently blocked both the basal and the CCK-stimulated p70s6k activity, and this inhibition was reversed by an excess of FK-506. The phosphatidylinositol 3-kinase inhibitor, wortmannin, potently inhibited p70s6k activation by CCK, whereas the tyrosine kinase inhibitor genistein had only a partial effect. Neither rapamycin nor wortmannin inhibited amylase release at concentrations that inhibited p70s6k activity. Thus the activation pathway of p70s6k by CCK is not mediated by PKC or mobilization of intracellular calcium but seems to be mediated by phosphatidylinositol 3-kinase. The effect of rapamycin to inhibit p70s6k activity is mediated by binding to the immunophyllin FK-506-binding protein of 12 kDa. The p70s6k is not involved in the secretion of digestive enzymes induced by CCK.

Monoclonal antibody to the human insulin receptor, but not insulin, stimulates S6 kinase via human insulin receptors mutated at three major tyrosine autophosphorylation sites

Studies were carried out to examine the role of the major insulin receptor tyrosine autophosphorylation sites in stimulation of S6 kinase activity. For these studies, we employed HTC rat hepatoma cells transfected with and expressing human insulin receptors. In cells transfected with and expressing a large number of normal human insulin receptors (HTC-IR cells), the sensitivity of cells to insulin to stimulate S6 kinase was increased tenfold when compared to untransfected wild type HTC cells (HTC-WT cells). However, in cells transfected with and expressing a large number of mutated human insulin receptors where the tyrosines at three major autophosphorylation sites (1158, 1162, and 1163) were mutated to phenylalanines (HTC-F3 cells), there was no change in insulin sensitivity when compared to HTC-WT cells. We next studied the effect of a human-specific monoclonal antibody to the human insulin receptor, MA-5, on S6 kinase activation. In HTC-WT cells, MA-5 did not interact with endogenous rat insulin receptors and thus did not stimulate S6 kinase. In HTC-IR cells expressing normal human insulin receptors, MA-5 stimulated S6 kinase. Interestingly, MA-5, unlike insulin, was also able to stimulate S6 kinase in HTC-F3 cells expressing mutated receptors. In order to further understand the signaling mechanisms by MA-5 and insulin, two potential intermediate protein kinases were investigated. Neither insulin nor MA-5 appears to activate either microtubule-associated protein 2 (MAP-2) kinase or protein kinase C in these cells. These studies suggest therefore that: 1) insulin and MA-5 may signal S6 kinase activation by independent mechanisms that do not employ either MAP-2 kinase or protein kinase C; and 2) under certain circumstances, S6 kinase appears to be activated by mechanisms that are independent of insulin receptor tyrosine autophosphorylation.